Degradable porous PLGA/PCL membrane enable a lung alveoli-on-a-chip for modeling particulate-induced alveolar injury

This study develops a biodegradable PLGA/PCL membrane-based lung alveoli-on-a-chip that mimics the dynamic structural evolution of the lung interface to effectively model diesel particulate matter-induced injury and evaluate therapeutic interventions.

The Gist

Imagine your lungs as a bustling, high-security border crossing. On one side is the air you breathe (the "apical" side), and on the other is your bloodstream (the "basolateral" side). Between them lies a very thin, delicate wall made of two layers of cells: the epithelial layer (facing the air) and the endothelial layer (facing the blood). This wall is so thin—about the width of a human hair—that it allows oxygen to pass through easily while keeping harmful things out.

The problem is that when we breathe in bad stuff, like diesel exhaust from trucks and cars, this wall gets damaged. Scientists have tried to study this damage in a lab, but their usual tools are like trying to study a hurricane in a wind tunnel made of thick, unbreakable plastic. They can't mimic the thinness of the lung wall, the way it stretches when we breathe, or how it changes over time.

This paper introduces a brand new, high-tech "lung in a box" (a Lung-on-a-Chip) that solves these problems using a special, self-changing material. Here is how it works, broken down into simple concepts:

1. The "Smart" Wall: A Degradable Membrane

Most lab models use a static plastic sheet to separate the air and blood sides. It's like a permanent, unchanging fence.

The researchers built a new wall using a mix of two plastics: PLGA and PCL.

• The Analogy: Think of this wall like a sugar cookie that slowly dissolves in your mouth.
  • The PLGA part is the sugar. It dissolves (degrades) over time. As it dissolves, the wall gets thinner and develops more holes (porosity). This mimics how the real lung wall might change or thin out during disease or inflammation.
  • The PCL part is the chocolate chips inside the cookie. Even as the sugar dissolves, the chocolate chips stay strong, keeping the cookie from falling apart. This ensures the wall stays sturdy enough to stretch and bounce back, just like a real lung stretching when you take a deep breath.

By the time the experiment is over, the wall has naturally evolved from a thick sheet into a super-thin, highly porous membrane, just like the real thing.

2. The Breathing Machine

A lung isn't just a static bag; it moves. Every time you inhale, your lungs stretch.

• The Analogy: The researchers put this "cookie wall" inside a device that acts like a mechanical accordion. A robot arm gently pushes and pulls the wall, stretching it by 10% (simulating a deep breath) 20 times a minute. This tells the cells, "Hey, you're in a real lung, not a petri dish!"

3. The Test: Diesel Exhaust Attack

Once the "lung" was built with human lung cells on both sides, the researchers tested it with Diesel Particulate Matter (DPM)—the black soot from truck exhaust.

• The Setup: They sprayed the soot onto the "air" side of the chip.
• The Result: The soot didn't just stay on the surface. It tore through the wall.
  • Cell Death: The cells on both sides (air side and blood side) started dying.
  • Leakage: The wall became "leaky," letting things pass through that shouldn't.
  • Damage: The cells showed signs of severe stress, like oxidative damage (rusting from the inside) and DNA breaks (torn instruction manuals).
  • The Big Discovery: The damage wasn't just on the air side; it traveled all the way through to the blood side. This proves that breathing in diesel fumes doesn't just hurt your lungs; it can directly damage your blood vessels.

4. The Rescue Attempt: A Medicine Test

The researchers then tried to see if a drug could fix the damage. They used Roflumilast-N-oxide (RNO), a medicine used for COPD (a lung disease).

• The Analogy: Imagine the lung is a house on fire. The researchers wanted to see if this medicine was a fire extinguisher or just a fire alarm.
• The Result: The medicine was a great fire alarm. It successfully stopped the "smoke" (inflammation) and the "heat" (oxidative stress). However, it was a bad fire extinguisher. It couldn't put out the actual fire (it didn't stop the cells from dying or fix the broken wall).
• Why this matters: This tells doctors that while this drug helps calm the immune system's panic, it might not be enough to actually repair the physical damage caused by pollution. We might need a different kind of "repair crew" to fix the wall itself.

Why This Matters

This "Lung-on-a-Chip" is a game-changer because:

1. It's Realistic: It uses human cells, breathes like a human, and has a wall that changes over time.
2. It's Dynamic: It shows us that pollution doesn't just hurt the surface; it travels through the whole system.
3. It's a Better Tester: It helps scientists see exactly how a drug works (does it stop the panic, or does it fix the structure?), which could lead to better treatments for lung diseases caused by pollution.

In short, the researchers built a tiny, breathing, self-changing lung model that finally lets us see exactly how bad air pollution destroys our lungs from the inside out.

Technical Summary

1. Problem Statement

Current in vitro models for studying lung toxicity, particularly regarding airborne particulate matter (PM) like diesel particulate matter (DPM), suffer from significant physiological limitations:

• Lack of Structural Fidelity: Conventional Transwell® assays and standard lung-on-a-chip devices use non-degradable, relatively thick synthetic membranes that fail to recapitulate the ultrathin (~1–2 µm) nature of the native alveolar air-blood barrier.
• Static Transport Properties: Existing membranes have fixed pore architectures that do not mimic the dynamic structural remodeling and transport evolution of the native lung interstitium.
• Limited Mechanistic Insight: The inability to faithfully reproduce the air-liquid interface (ALI), cyclic mechanical strain (breathing), and the coupled epithelial-endothelial crosstalk hinders the understanding of how particulates cause trans-barrier injury and systemic effects.

2. Methodology

The authors developed a novel lung alveoli-on-a-chip platform centered on a biodegradable, porous membrane scaffold.

• Membrane Fabrication (PLGA/PCL):

  • Materials: A blend of Poly(lactic-co-glycolic acid) (PLGA) and Polycaprolactone (PCL). PLGA provides rapid hydrolytic degradation, while PCL offers mechanical elasticity and stability.
  • Process: A porogen-assisted non-solvent-induced phase separation (NIPS) technique was used. A solution of PLGA/PCL and camphene (porogen) in acetone was spin-coated, immersed in water (nonsolvent) to induce phase separation, and freeze-dried to sublimate the camphene, creating an interconnected porous structure.
  • Optimization: Various blend ratios (10:0, 9:1, 8:2, 7:3) were tested. An 8:2 PLGA:PCL ratio was selected as the optimal balance between degradation-driven porosity enhancement and mechanical integrity.

• Device Assembly & Culture:

  • The membrane was integrated into a PDMS microfluidic device separating apical (air) and basolateral (liquid) chambers.
  • Cell Types: Human primary alveolar epithelial cells (HPAECs) were seeded on the apical side, and human lung microvascular endothelial cells (HMVECs) on the basolateral side.
  • Culture Conditions: Cells were cultured under an Air-Liquid Interface (ALI) with breathing-mimetic cyclic mechanical strain (10% linear strain at 0.33 Hz).

• Degradation Monitoring:

  • The system was designed so that PLGA degradation over time (approx. 9 days) would progressively increase surface porosity and reduce membrane thickness, mimicking the thinning of the alveolar barrier.

• Toxicity & Therapeutic Assessment:

  • Toxicant: Diesel Particulate Matter (DPM) was applied to the apical surface at varying doses (0–60 µg/cm²).
  • Therapeutic: Roflumilast-N-oxide (RNO), a PDE4 inhibitor, was administered to the basolateral compartment to test for mitigation of injury.
  • Readouts: Cell viability (Live/Dead), barrier permeability (FITC-dextran), oxidative stress (ROS/H₂O₂), genotoxicity (γ-H2AX), and inflammatory cytokine secretion.

3. Key Contributions

• Dynamic Interface Material: Introduction of a degradable PLGA/PCL membrane that evolves structurally during culture. Unlike static membranes, this scaffold increases in porosity (40%) and decreases in thickness (3 µm) over time, directly modulating transport properties to better mimic the native alveolar interface.
• Mechanical Resilience: Demonstrated that the PCL component maintains mechanical integrity under cyclic stretching despite the degradation of the PLGA component, allowing for long-term ALI culture with breathing motions.
• Layer-Resolved Toxicity Modeling: Established a platform capable of detecting trans-barrier propagation of injury, showing that apical DPM exposure affects both the epithelial and endothelial layers simultaneously.
• Pharmacological Discrimination: Showed the platform's ability to distinguish between different types of cellular responses, specifically separating oxidative/inflammatory mitigation from barrier repair.

4. Key Results

• Membrane Characterization:

  • The 8:2 blend achieved a surface porosity increase from ~23% to ~40% and a thickness reduction from ~6 µm to ~3 µm over 9 days.
  • Mass loss was moderate (15.3% for 7:3 blend), confirming PCL stabilizes the structure.
  • Permeability increased 1.68-fold compared to standard Transwells and further increased 1.50-fold after degradation.

• Barrier Formation:

  • Co-cultured cells formed confluent monolayers with functional tight junctions (ZO-1) and adherens junctions (VE-cadherin).
  • Cell viability remained high (>93%) throughout the culture period under dynamic strain.

• DPM Toxicity:

  • Dose-Dependent Injury: DPM exposure caused significant cytotoxicity, barrier disruption (increased permeability), ROS elevation, and DNA damage (γ-H2AX) in both cell layers.
  • Trans-Barrier Effect: Endothelial cells showed comparable viability loss to epithelial cells, confirming DPM particles traverse the porous membrane to reach the vascular side.

• Therapeutic Modulation (RNO):

  • Selective Protection: RNO treatment significantly reduced ROS levels and pro-inflammatory cytokine secretion.
  • Limited Structural Rescue: RNO did not significantly restore cell viability or barrier integrity (permeability) in the short term, indicating that while inflammation can be chemically suppressed, structural barrier repair requires different mechanisms.

5. Significance

This work represents a paradigm shift in organ-on-a-chip design by moving from static scaffolds to dynamically evolving interfaces.

• Physiological Relevance: By allowing the membrane to thin and become more porous over time, the model better simulates the transport constraints and structural dynamics of the human alveolar barrier.
• Mechanistic Insight: The platform successfully decouples different injury pathways, revealing that anti-inflammatory drugs (like RNO) may mitigate oxidative stress without immediately repairing physical barrier damage. This nuance is critical for drug development and understanding disease progression.
• Future Applications: The system provides a robust, human-relevant tool for studying chronic particulate exposure, cardiovascular-pulmonary crosstalk, and screening therapeutics for air pollution-related diseases. The concept of "degradation-driven structural evolution" could be extended to other barrier tissues (e.g., gut, blood-brain barrier) where dynamic remodeling is physiologically relevant.